Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer

PURPOSE: Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with activity in HER2-amplified metastatic breast cancer (MBC). Its role in non–HER2-amplified MBC remains unclear. EGF30001, a phase III trial of lapatinib and pacli...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Finn, Richard S., Press, Michael F., Dering, Judy, Arbushites, Michael, Koehler, Maria, Oliva, Cristina, Williams, Lisa S., Di Leo, Angelo
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2009
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2799151/
https://ncbi.nlm.nih.gov/pubmed/19620495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.18.1925
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados